从氧酸盐过渡到低氧酸盐的麻醉症患者的剂量和过渡特征:来自现实世界TENOR研究的数据
Aatif M Husain1, Phyllis C Zee2, Eileen B Leary3
1Duke University Medical Center, Durham, NC, USA.
Sleep medicine
|December 16, 2023
概括
麻醉症患者在现实研究中成功从氧酸盐 (SXB) 转换为低氧酸盐 (LXB). 这种转换的主要驱动因素是LXB的减少含量,以改善长期健康.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 患者报告的结果
背景情况:
- 麻醉症是一种慢性神经系统疾病,影响睡眠和清醒的调节.
- 氧酸盐 (SXB) 是用于治疗麻醉症的药物,但其高含量引起健康问题.
- 低氧酸盐 (LXB) 提供了一种减少的替代品,用于治疗麻醉症.
研究的目的:
- 评估麻醉症患者从SXB切换到LXB的现实世界的过渡体验.
- 确定患者报告过渡到LXB的原因.
- 在现实环境中评估LXB的安全性和耐受性.
主要方法:
- 服用Oxybate的麻醉症患者的过渡体验 (TENOR) 研究是一项前性,观察性,虚拟研究.
- 85名美国成年人从SXB过渡到LXB的麻醉症被纳入.
- 长度数据在转换后的21周内被收集.
主要成果:
- 大多数参与者 (93%) 由于较低的含量而转化为长期健康益处.
- 转换主要采用了一种每克SXB转换为LXB的剂量转换策略 (87%).
- 参与者继续每晚两次使用LXB疗法 (97%),平均最终剂量为7.9g.
结论:
- 从SXB到LXB的现实世界过渡是可行的,主要是由于减少摄入的愿望.
- 在这种过渡过程中,通常采用每克对每克的剂量策略.
- 对于寻求减轻与有关的健康风险的麻醉症患者来说,LXB代表了一个可行的替代方案.
相关概念视频
Narcolepsy
106
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
106
Sleep-Wake Cycles
1.4K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
1.4K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
153
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
153
Sedatives and Hypnotics Drugs: Miscellaneous Agents
179
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
179
Management of Insomnia
255
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
255
Antiepileptic Drugs: Potassium Channel Activators
184
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
184


